# AstraZeneca (AZN) SEC filings: latest 20-F and 6-K reports

URL: https://funkfolio.com/stock/AZN/filings

> AstraZeneca (AZN) SEC filings from EDGAR: 20-F filed Feb 24, 2026, 6-K filed Nov 16, 2026. 140 filings in the last 12 months.

---

## AstraZeneca (AZN) SEC filings

AstraZeneca's latest annual report is a Form 20-F filed on February 24, 2026 for the period ended December 31, 2025. Its latest Form 6-K report was filed on November 16, 2026. EDGAR lists 140 filings for it in the last twelve months.

### Key facts

- **Latest annual report:** 20-F, Feb 24, 2026
- **Latest 6-K:** 6-K, Nov 16, 2026
- **Filings, last 12 months:** 140
- **Insider forms, last 12 months:** 9 Forms 3, 4 and 5
- **13D and 13G, last 12 months:** 3
- **SEC central index key:** 0000901832

Filings as listed by SEC EDGAR at Nov 18, 2026, 10:46 UTC (re-read at most hourly). Source: [SEC EDGAR filings for CIK 0000901832](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832). Every form links to its document on sec.gov. Older filings are in EDGAR's archive; the tables here cover its recent list (at least the last year).

### Annual and quarterly reports

AstraZeneca: annual and quarterly reports filed with the SEC

| Form | Filed | Period ended | Document |
| --- | --- | --- | --- |
| [20-F](https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm) | Feb 24, 2026 | Dec 31, 2025 | Annual report of a foreign private issuer |
| [20-F](https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/azn-20241231x20f.htm) | Feb 18, 2025 | Dec 31, 2024 | FORM 20-F |
| [20-F](https://www.sec.gov/Archives/edgar/data/901832/000110465924025553/azn-20211231x20f.htm) | Feb 20, 2024 | Dec 31, 2023 | FORM 20-F |
| [20-F](https://www.sec.gov/Archives/edgar/data/901832/000110465923023818/azn-20221231x20f.htm) | Feb 21, 2023 | Dec 31, 2022 | FORM 20-F |
| [20-F](https://www.sec.gov/Archives/edgar/data/901832/000110465922025720/azn-20211231x20f.htm) | Feb 22, 2022 | Dec 31, 2021 | FORM 20F |
| [20-F](https://www.sec.gov/Archives/edgar/data/901832/000110465921022456/a21-3954_120f.htm) | Feb 16, 2021 | Dec 31, 2020 | Annual report of a foreign private issuer |
| [20-F](https://www.sec.gov/Archives/edgar/data/901832/000110465920028557/a20-5700_120f.htm) | Mar 3, 2020 | Dec 31, 2019 | Annual report of a foreign private issuer |

Amended reports are marked. The period is the fiscal year or quarter the report covers.

#### Reports of a foreign private issuer (Form 6-K)

AstraZeneca: reports on Form 6-K

| Form | Filed | Report date | Document |
| --- | --- | --- | --- |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426009815/a2430d.htm) | Nov 16, 2026 | Nov 16, 2026 | BAXFENDY RECOMMENDED FOR APPROVAL IN THE EU |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426009811/a2426d.htm) | Nov 16, 2026 | Nov 16, 2026 | IMFINZI + EV APPROVED IN US IN BLADDER CANCER |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426009808/a2301d.htm) | Nov 16, 2026 | Nov 16, 2026 | KLYGEFA (GEFURULIMAB) APPROVED IN THE US |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426009804/a2029d.htm) | Nov 16, 2026 | Nov 16, 2026 | KLYGEFA (GEFURULIMAB) APPROVED IN THE EU |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426009359/a2828b.htm) | Nov 2, 2026 | Nov 2, 2026 | ADMISSION OF FURTHER SECURITIES TO TRADING |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426009357/a2825b.htm) | Nov 2, 2026 | Nov 2, 2026 | TOTAL VOTING RIGHTS |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426009256/a0835b.htm) | Oct 30, 2026 | Oct 30, 2026 | 3RD QUARTER RESULTS |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426009155/a6054a.htm) | Oct 27, 2026 | Oct 27, 2026 | ENHERTU APPROVED IN EU FOR HER2-POSITIVE EBC |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426009093/a9580z.htm) | Oct 22, 2026 | Oct 22, 2026 | ULTOMIRIS APPROVED IN US IN IGAN |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008783/a6290x.htm) | Oct 5, 2026 | Oct 5, 2026 | ASTRAZENECA COMPLETES EQUITY INVESTMENT IN SUMMIT |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008760/a3874x.htm) | Oct 2, 2026 | Oct 2, 2026 | AZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008741/a2108x.htm) | Oct 1, 2026 | Oct 1, 2026 | ADMISSION OF FURTHER SECURITIES TO TRADING |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008739/a2082x.htm) | Oct 1, 2026 | Oct 1, 2026 | TOTAL VOTING RIGHTS |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008615/a6704w.htm) | Sep 29, 2026 | Sep 29, 2026 | ASTRAZENECA ANNOUNCES EQUITY INVESTMENT IN SUMMIT |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008520/a8652v.htm) | Sep 23, 2026 | Sep 23, 2026 | TRIXEO APPROVED IN EU FOR ASTHMA |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008478/a4455v.htm) | Sep 21, 2026 | Sep 21, 2026 | KLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMP |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008476/a4447v.htm) | Sep 21, 2026 | Sep 21, 2026 | ENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008438/a2662v.htm) | Sep 18, 2026 | Sep 18, 2026 | DIRECTOR/PDMR SHAREHOLDING |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008369/a8240u.htm) | Sep 15, 2026 | Sep 15, 2026 | DIRECTOR/PDMR SHAREHOLDING |
| [6-K](https://www.sec.gov/Archives/edgar/data/901832/000165495426008367/a8243u.htm) | Sep 15, 2026 | Sep 15, 2026 | DIRECTOR/PDMR SHAREHOLDING |

The latest 20 of 819 in EDGAR's recent list. A 6-K carries what the company publishes at home — results, press releases, notices to shareholders.

### Insider forms (3, 4 and 5)

AstraZeneca: insider forms 3, 4 and 5 filed per month over the last twelve months

| Month | Forms filed |
| --- | --- |
| Nov 2026 | 1 |
| Oct 2026 | 1 |
| Sep 2026 | 1 |
| Aug 2026 | 1 |
| Jul 2026 | 1 |
| Jun 2026 | 1 |
| May 2026 | 2 |
| Apr 2026 | 0 |
| Mar 2026 | 1 |
| Feb 2026 | 0 |
| Jan 2026 | 0 |
| Dec 2025 | 0 |

AstraZeneca: the latest insider forms

| Form | Filed | Transaction date |
| --- | --- | --- |
| [4](https://www.sec.gov/Archives/edgar/data/901832/000212241126000003/xslF345X06/primary_doc.xml) | Nov 10, 2026 | Nov 6, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/901832/000212241126000002/xslF345X06/primary_doc.xml) | Oct 8, 2026 | Oct 6, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/901832/000110465926107055/xslF345X06/tm2625297-1_4seq1.xml) | Sep 11, 2026 | Aug 8, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/901832/000212241126000001/xslF345X06/primary_doc.xml) | Aug 7, 2026 | Aug 6, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/901832/000110465926081807/xslF345X06/tm2619989-1_4seq1.xml) | Jul 8, 2026 | Jul 6, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/901832/000110465926074570/xslF345X06/tm2617978-1_4seq1.xml) | Jun 16, 2026 | Jun 8, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/901832/000110465926065693/xslF345X06/tm2615366-1_4seq1.xml) | May 22, 2026 | May 20, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/901832/000110465926057906/xslF345X06/tm2614063-1_4seq1.xml) | May 8, 2026 | Apr 7, 2026 |
| [3](https://www.sec.gov/Archives/edgar/data/901832/000110465926032249/xslF345X06/tm269379-1_3seq1.xml) | Mar 19, 2026 | Mar 18, 2026 |
| [4](https://www.sec.gov/Archives/edgar/data/901832/000110465921036719/xslF345X03/a4.xml) | Mar 16, 2021 | Mar 15, 2021 |
| [4](https://www.sec.gov/Archives/edgar/data/901832/000110465920012390/xslF345X03/a4.xml) | Feb 7, 2020 | Dec 19, 2019 |
| [3](https://www.sec.gov/Archives/edgar/data/901832/000110465920012389/xslF345X02/a3.xml) | Feb 7, 2020 | Dec 19, 2019 |
| [4](https://www.sec.gov/Archives/edgar/data/901832/000089924319025369/xslF345X03/doc4.xml) | Oct 9, 2019 | Oct 7, 2019 |
| [3 (amended)](https://www.sec.gov/Archives/edgar/data/901832/000089924319025368/xslF345X02/doc3a.xml) | Oct 9, 2019 | Oct 2, 2019 |
| [3](https://www.sec.gov/Archives/edgar/data/901832/000089924319024821/xslF345X02/doc3.xml) | Oct 2, 2019 | Oct 2, 2019 |

Each form is filed by the insider about their own holding; the trade details are inside the form on sec.gov. Counts include amendments. The current month is counted to date.

### Ownership reports (Schedules 13D and 13G)

AstraZeneca: Schedule 13D and 13G beneficial ownership reports

| Form | Filed | Event date |
| --- | --- | --- |
| [Schedule 13G](https://www.sec.gov/Archives/edgar/data/901832/000210011926000022/xslSCHEDULE_13G_X02/primary_doc.xml) | Apr 28, 2026 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/901832/000110465926011303/xslSCHEDULE_13G_X01/primary_doc.xml) | Feb 6, 2026 | — |
| [Schedule 13D (amended)](https://www.sec.gov/Archives/edgar/data/901832/000110465926011298/xslSCHEDULE_13D_X01/primary_doc.xml) | Feb 6, 2026 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/901832/000205211325001438/xslSCHEDULE_13G_X01/primary_doc.xml) | Apr 23, 2025 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/901832/000110465925033481/xslSCHEDULE_13G_X01/primary_doc.xml) | Apr 10, 2025 | — |
| [Schedule 13D (amended)](https://www.sec.gov/Archives/edgar/data/901832/000110465925005814/xslSCHEDULE_13D_X01/primary_doc.xml) | Jan 24, 2025 | — |
| [Schedule 13G](https://www.sec.gov/Archives/edgar/data/901832/000110465924111584/tm2426761d1_sc13g.htm) | Oct 28, 2024 | — |
| [Schedule 13G](https://www.sec.gov/Archives/edgar/data/901832/000110465924107836/tm2425992d1_sc13g.htm) | Oct 11, 2024 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/901832/000110465924013882/tm245762d1_sc13ga.htm) | Feb 12, 2024 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/901832/000108636424002650/gb0009895292_012424.txt) | Jan 24, 2024 | — |
| [Schedule 13D (amended)](https://www.sec.gov/Archives/edgar/data/901832/000110465923118991/tm2330912d1_sc13da.htm) | Nov 16, 2023 | — |
| [Schedule 13D](https://www.sec.gov/Archives/edgar/data/901832/000110465923116366/tm2330279d1_sc13d.htm) | Nov 9, 2023 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/901832/000110465923018084/tm235883d2_sc13ga.htm) | Feb 10, 2023 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/901832/000110465923018079/tm235883d1_sc13ga.htm) | Feb 10, 2023 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/901832/000130655023003090/gb0009895292_012423.txt) | Jan 24, 2023 | — |
| [Schedule 13G](https://www.sec.gov/Archives/edgar/data/901832/000083423722010196/gb0009895292_070822.txt) | Jul 8, 2022 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/901832/000083423722007784/gb0009895292_020722.txt) | Feb 7, 2022 | — |
| [Schedule 13G (amended)](https://www.sec.gov/Archives/edgar/data/901832/000167885822000071/SEC13G_Filing.htm) | Feb 4, 2022 | — |
| [Schedule 13G](https://www.sec.gov/Archives/edgar/data/901832/000110465921096237/tm2123282d1_sc13g.htm) | Jul 27, 2021 | — |
| [Schedule 13G](https://www.sec.gov/Archives/edgar/data/901832/000110465921047684/a21-12390_1sc13g.htm) | Apr 8, 2021 | — |

The latest 20 of 29 in EDGAR's recent list. Filed by the holder, not the company. EDGAR's list names the form and date; who filed it is in the document.

**Everything else (131 filings: registrations, prospectuses, Rule 144 notices, correspondence and more)**

AstraZeneca: other SEC filings

| Form | Filed | Period | Document |
| --- | --- | --- | --- |
| [11-K](https://www.sec.gov/Archives/edgar/data/901832/000168316826005159/astrazeneca_i11k.htm) | Jun 29, 2026 | Dec 31, 2025 | FORM 11-K |
| [25-NSE](https://www.sec.gov/Archives/edgar/data/901832/000087666126000484/xslF25X02/primary_doc.xml) | May 28, 2026 | — |  |
| [25-NSE](https://www.sec.gov/Archives/edgar/data/901832/000087666126000343/xslF25X02/primary_doc.xml) | Apr 8, 2026 | — |  |
| [CERT](https://www.sec.gov/Archives/edgar/data/901832/000087666126000201/AZN31B33A36030426.pdf) | Mar 4, 2026 | — | NYSE CERTIFICATION |
| [8-A12B](https://www.sec.gov/Archives/edgar/data/901832/000110465926022824/tm267648d1_8a12b.htm) | Mar 3, 2026 | — | FORM 8-A12B |
| [424B2](https://www.sec.gov/Archives/edgar/data/901832/000110465926021545/tm267138-4_424b2.htm) | Feb 27, 2026 | — | Prospectus |
| [FWP](https://www.sec.gov/Archives/edgar/data/901832/000110465926019812/tm267138d5_fwp.htm) | Feb 26, 2026 | — |  |
| [424B2](https://www.sec.gov/Archives/edgar/data/901832/000110465926019420/tm267138-2_424b2.htm) | Feb 25, 2026 | — | Prospectus |
| [IRANNOTICE](https://www.sec.gov/Archives/edgar/data/901832/000110465926019141/tm261135d2_irannotice.htm) | Feb 24, 2026 | — |  |
| [S-8](https://www.sec.gov/Archives/edgar/data/901832/000110465926009284/tm264269d1_s8.htm) | Feb 2, 2026 | — | FORM S-8 |
| [25](https://www.sec.gov/Archives/edgar/data/901832/000110465926008613/tm264197d1_25.htm) | Jan 30, 2026 | — | FORM 25 |
| [CERT](https://www.sec.gov/Archives/edgar/data/901832/000087666126000055/AZNNotes012226.pdf) | Jan 22, 2026 | — | NYSE CERTIFICATION |
| [8-A12B](https://www.sec.gov/Archives/edgar/data/901832/000110465926005799/tm263731d2_8a12b.htm) | Jan 22, 2026 | — |  |
| [CERT](https://www.sec.gov/Archives/edgar/data/901832/000087666126000054/AZN012226.pdf) | Jan 22, 2026 | — | NYSE CERTIFICATION |
| [8-A12B](https://www.sec.gov/Archives/edgar/data/901832/000110465926005772/tm263731d1_8a12b.htm) | Jan 22, 2026 | — |  |
| [25-NSE](https://www.sec.gov/Archives/edgar/data/901832/000135445725001137/xslF25X02/primary_doc.xml) | Nov 14, 2025 | — |  |
| [144](https://www.sec.gov/Archives/edgar/data/901832/000195004725008803/xsl144X01/primary_doc.xml) | Nov 12, 2025 | — | Notice of proposed sale |
| [11-K](https://www.sec.gov/Archives/edgar/data/901832/000168316825004771/astra_11k.htm) | Jun 26, 2025 | Dec 31, 2024 | FORM 11-K |
| [IRANNOTICE](https://www.sec.gov/Archives/edgar/data/901832/000110465925014758/tm251208d2_irannotice.htm) | Feb 18, 2025 | — |  |
| [EFFECT](https://www.sec.gov/Archives/edgar/data/901832/999999999525000324/xslEFFECTX01/primary_doc.xml) | Feb 5, 2025 | — |  |
| [F-6](https://www.sec.gov/Archives/edgar/data/901832/000119380525000067/e664152_f6-az.htm) | Jan 21, 2025 | — |  |
| [11-K](https://www.sec.gov/Archives/edgar/data/901832/000168316824004498/astrazeneca_11k-123123.htm) | Jun 26, 2024 | Dec 31, 2023 | ANNUAL REPORT |
| [25-NSE](https://www.sec.gov/Archives/edgar/data/901832/000135445724000385/xslF25X02/primary_doc.xml) | Jun 4, 2024 | — |  |
| [DFAN14A](https://www.sec.gov/Archives/edgar/data/901832/000110465924036230/tm249109d2_dfan14a.htm) | Mar 19, 2024 | — |  |
| [F-3ASR](https://www.sec.gov/Archives/edgar/data/901832/000110465924036178/tm248869-1_f3.htm) | Mar 19, 2024 | — |  |
| [CERT](https://www.sec.gov/Archives/edgar/data/901832/000135445724000128/AZN_8A_Cert_Notes.pdf) | Mar 6, 2024 | — |  |
| [8-A12B](https://www.sec.gov/Archives/edgar/data/901832/000110465924031066/tm246099d7_8a12b.htm) | Mar 5, 2024 | — |  |
| [424B2](https://www.sec.gov/Archives/edgar/data/901832/000110465924027015/tm246099-2_424b2.htm) | Feb 23, 2024 | — | Prospectus |
| [FWP](https://www.sec.gov/Archives/edgar/data/901832/000110465924026163/tm246099d3_fwp.htm) | Feb 22, 2024 | — |  |
| [SC TO-T (amended)](https://www.sec.gov/Archives/edgar/data/901832/000110465924025822/tm2332933d17_sctota.htm) | Feb 21, 2024 | — |  |
| [424B2](https://www.sec.gov/Archives/edgar/data/901832/000110465924025819/tm246099-1_424b2.htm) | Feb 21, 2024 | — | Prospectus |
| [S-8](https://www.sec.gov/Archives/edgar/data/901832/000110465924025610/tm246444d1_s8.htm) | Feb 20, 2024 | — | FORM S-8 |
| [IRANNOTICE](https://www.sec.gov/Archives/edgar/data/901832/000110465924025568/tm2333142d2_irannotice.htm) | Feb 20, 2024 | — |  |
| [SC TO-T (amended)](https://www.sec.gov/Archives/edgar/data/901832/000110465924025223/tm2332933d15_sctota.htm) | Feb 20, 2024 | — |  |
| [SC TO-T (amended)](https://www.sec.gov/Archives/edgar/data/901832/000110465924024104/tm2332933d14_sctota.htm) | Feb 15, 2024 | — |  |
| [SC TO-T (amended)](https://www.sec.gov/Archives/edgar/data/901832/000110465924005033/tm2332933d13_sctota.htm) | Jan 19, 2024 | — |  |
| [SC TO-T (amended)](https://www.sec.gov/Archives/edgar/data/901832/000110465924003090/tm2332933d10_sctota.htm) | Jan 11, 2024 | — |  |
| [CORRESP](https://www.sec.gov/Archives/edgar/data/901832/000110465924003086/filename1.htm) | Jan 10, 2024 | — |  |
| [SC TO-T](https://www.sec.gov/Archives/edgar/data/901832/000110465923129493/tm2332933-1_sctot.htm) | Dec 27, 2023 | — |  |
| [SC TO-C](https://www.sec.gov/Archives/edgar/data/901832/000110465923125421/tm2332587d2_sctoc.htm) | Dec 12, 2023 | — |  |
| [25-NSE](https://www.sec.gov/Archives/edgar/data/901832/000135445723000837/xslF25X02/primary_doc.xml) | Nov 14, 2023 | — |  |
| [144](https://www.sec.gov/Archives/edgar/data/901832/000110465923116769/xsl144X01/primary_doc.xml) | Nov 13, 2023 | — | Notice of proposed sale |
| [25-NSE](https://www.sec.gov/Archives/edgar/data/901832/000135445723000587/xslF25X02/primary_doc.xml) | Aug 16, 2023 | — |  |
| [11-K](https://www.sec.gov/Archives/edgar/data/901832/000168316823004490/astrazeneca_11k-123122.htm) | Jun 28, 2023 | Dec 31, 2022 | ANNUAL REPORT |
| [25-NSE](https://www.sec.gov/Archives/edgar/data/901832/000135445723000365/xslF25X02/primary_doc.xml) | May 25, 2023 | — |  |
| [CERT](https://www.sec.gov/Archives/edgar/data/901832/000135445723000177/8A_Cert_AZN.pdf) | Mar 15, 2023 | — |  |
| [8-A12B](https://www.sec.gov/Archives/edgar/data/901832/000110465923031804/tm2372204d9_8a12b.htm) | Mar 13, 2023 | — |  |
| [424B2](https://www.sec.gov/Archives/edgar/data/901832/000110465923027978/tm237224-6_424b2.htm) | Mar 2, 2023 | — | Prospectus |
| [FWP](https://www.sec.gov/Archives/edgar/data/901832/000110465923026907/tm237224d3_fwp.htm) | Mar 1, 2023 | — |  |
| [424B2](https://www.sec.gov/Archives/edgar/data/901832/000110465923026467/tm237224-5_424b2.htm) | Feb 28, 2023 | — | Prospectus |
| [SC TO-T (amended)](https://www.sec.gov/Archives/edgar/data/901832/000110465923024916/tm232683d10_sctota.htm) | Feb 24, 2023 | — |  |
| [SC TO-T (amended)](https://www.sec.gov/Archives/edgar/data/901832/000110465923024430/tm232683d9_sctot.htm) | Feb 23, 2023 | — |  |
| [IRANNOTICE](https://www.sec.gov/Archives/edgar/data/901832/000110465923023824/tm2230344d2_irannotice.htm) | Feb 21, 2023 | — |  |
| [SC TO-T (amended)](https://www.sec.gov/Archives/edgar/data/901832/000110465923010674/tm232683d8_sctota.htm) | Feb 3, 2023 | — |  |
| [SC TO-T](https://www.sec.gov/Archives/edgar/data/901832/000110465923005595/tm232683-2_sctot.htm) | Jan 23, 2023 | — |  |
| [SC TO-C](https://www.sec.gov/Archives/edgar/data/901832/000110465923002291/tm232683d1_sctoc.htm) | Jan 9, 2023 | — |  |
| [11-K](https://www.sec.gov/Archives/edgar/data/901832/000168316822004659/astrazeneca_11k-123121.htm) | Jun 29, 2022 | Dec 31, 2021 | ANNUAL REPORT |
| [25-NSE](https://www.sec.gov/Archives/edgar/data/901832/000135445722000341/xslF25X02/primary_doc.xml) | Jun 10, 2022 | — |  |
| [25-NSE](https://www.sec.gov/Archives/edgar/data/901832/000135445722000336/xslF25X02/primary_doc.xml) | Jun 9, 2022 | — |  |
| [IRANNOTICE](https://www.sec.gov/Archives/edgar/data/901832/000110465922025730/tm2134205d2_irannotice.htm) | Feb 22, 2022 | — |  |

The latest 60 of 131 in EDGAR's recent list.

### What the forms are

**Form 3 — Initial statement of beneficial ownership**

An insider's first statement of holdings in the company's equity securities. Insiders are officers, directors and holders of more than 10 percent of a class of its registered equity securities.

**Form 4 — Statement of changes in beneficial ownership**

An insider's transactions in the company's equity securities, disclosed within two business days of the transaction.

**Form 144 — Notice of proposed sale**

In the SEC's Forms Index: notice of proposed sale of securities pursuant to Rule 144.

**Form 10-K — Annual report**

Audited annual financial statements, a discussion of material risk factors, and management's discussion and analysis of the results for the prior fiscal year.

**Form 10-Q — Quarterly report**

Unaudited quarterly financial statements, updates on material risks, and management's discussion and analysis of the results for the prior fiscal quarter.

**Form 8-K — Current report**

Discloses material events or information the company chooses or is required to make public before its next scheduled quarterly or annual report. Each report lists the items it covers.

**Form 20-F — Annual report of a foreign private issuer**

Audited financial statements of the foreign private issuer and a discussion of its financial results; the same form is used to register a class of securities.

**Form 6-K — Report of a foreign private issuer**

Filed with press releases, communications to security holders, and disclosures the company's home country requires it to make to security holders.

**Schedule 13D — Schedule 13D beneficial ownership report**

Filed when a party acquires more than five percent of a class of the company's registered voting securities; also used to disclose later changes to the holding.

**Schedule 13G — Schedule 13G beneficial ownership report**

Filed when a party acquires more than five percent of a class of the company's registered voting securities as a passive investment.

**Form S-8 — Registration statement for employee plans**

In the SEC's Forms Index: registration statement under the Securities Act of 1933 for securities to be offered to employees under certain plans.

**Form 424B — Prospectus**

A document disclosing information about the company and an offering; it typically makes up a large part of the registration statement.

From the SEC's own descriptions: [SEC, Using EDGAR to Research Investments](https://www.sec.gov/search-filings/edgar-search-assistance/using-edgar-research-investments); [SEC, Forms Index](https://www.sec.gov/submit-filings/forms-index); [SEC, Form 8-K and its items (PDF)](https://www.sec.gov/files/form8-k.pdf).

### Questions and answers

**Where is AstraZeneca's latest annual report (20-F)?**

AstraZeneca filed its latest Form 20-F with the SEC on February 24, 2026 for the period ended December 31, 2025. The table of annual and quarterly reports on this page links to the document on sec.gov.

**How many insider filings (Forms 3, 4 and 5) were there for AZN in the last year?**

9 insider forms in the twelve months to November 18, 2026, the latest a Form 4 filed on November 10, 2026. Officers, directors and holders of more than 10 percent of a class of the company's registered equity securities must disclose their holdings and transactions; a Form 4 is due within two business days of a trade.

**Has anyone reported owning more than 5% of AstraZeneca?**

EDGAR lists 3 Schedule 13D or 13G filings about AstraZeneca in the last twelve months, the latest on April 28, 2026. These are filed by a party that acquires more than five percent of a class of the company's voting securities; 13G is for passive investors.

### Learn

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “AstraZeneca (AZN) SEC filings: latest 20-F and 6-K reports”, data as of 18 November 2026. https://funkfolio.com/stock/AZN/filings

Underlying data: SEC EDGAR submissions (data.sec.gov).
